Entrepreneurial Thought Leader Speaker Series

Tools

Impact of Generics on the Biotechnology Industry - Joe McCracken (Genentech)
Date: 11/30/2006
Length: 2 minutes
Speaker(s): Joe McCracken
Sources: Stanford Technology Ventures Program
Description: Joe comments on the widely held debate in the biotechnology industry about the legality and effectiveness of generic drugs. Joe feels that as long as the follow-on biologics are effective and safe, they would be great for the
industry. He states the Genentech will compete by continually innovating better drugs.

Other Videos in Series

A Novel Approach Towards Sales and Research - Joe McCracken (Genentech)
Joe McCracken
11/30/2006
Summary: Joe discusses innovative practices put in place in the sales and research organizations within Genentech. He cites the 20% free time and incentives for publishing for scientists and the focus of the sales force on at most two
products as major reasons for Genentech's success both in the lab and the marketplace. Watch More
Genentech's Business Model - Joe McCracken (Genentech)
Joe McCracken
11/30/2006
Summary: Joe McCracken, Vice President of Business Development at Genentech, describes Genentech's business model where commercialization takes a back seat to science. He differentiates this from other typical pharmaceutical companies and
shows how this affects the culture at Genentech. He credits this approach for the successful innovation of several hugely profitable drugs. Watch More
Impact of Generics on the Biotechnology Industry - Joe McCracken (Genentech)
Joe McCracken
11/30/2006
Summary: Joe comments on the widely held debate in the biotechnology industry about the legality and effectiveness of generic drugs. Joe feels that as long as the follow-on biologics are effective and safe, they would be great for the
industry. He states the Genentech will compete by continually innovating better drugs. Watch More
Venture Capital in Biotech - Joe McCracken (Genentech)
Joe McCracken
11/30/2006
Summary: Joe discusses the recent lack of investment in biotech. He explains that after the biotech bubble in 2000, VCs have been hesitant in investing in biotech companies, and this has led to a slowdown in innovation in the
industry. Watch More
Why is Genentech the Best Company to Work for? - Joe McCracken (Genentech)
Joe McCracken
11/30/2006
Summary: In 2006, Fortune ranked Genentech as the best company to work for. McCracken shares their secret: it is the empowerment of the employees and the validation of their hard work, which comes in the form of gratified
patients. Watch More

comments powered by Disqus

Search e360TV

Stay Connected

Email Newsletter Signup

Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.

Email Newsletters

Want to be up-to-date with the latest news and updates from Entrepreneurship.org? To subscribe, just give us your email address below; you'll choose which e-newsletters you'd like to receive on the next screen.